source
- Epkinly shows 51% lower risk of progression in frontline DLBCL trial, boosting hopes for expanded approvalNew Phase 3 data from the Epkinly and R-CHOP combination in diffuse large B cell lymphoma showed a 51% reduction in the risk of disease progression or death compared with standard therapy. The stud…
- Dutch court orders Merck to halt subcutaneous Keytruda sales in eight European countriesA Dutch court has issued an injunction that requires Merck to stop manufacturing and selling the injectable, subcutaneous formulation of its cancer immunotherapy Keytruda in eight European countrie…